Bluebird bio Inc (BLUE)

I think it will cost 2$ in 25 and not 10$

2025 10$

Will they release news Nov 4th 2024 when they release their earnings report?

Se non è stato toccato il fondo in questi giorni allora siamo messi molto male - Si prospetta un fallimento per i detentori Long -

This is not the first ohne, he flight to the moon, and not the last ohne!

Da geht's um Milliarden, nicht um Schnäppchen!

This is a Rocket!...ohne Bremsen wird zum Mond knallen, ist ja nicht der erste, wird auch nicht der letzte sein!

If it goes to $10 it will be sold all in 1 day...

No one dare to buy dropping stocks...

Make it higher, people like stocks go up....

What is the maximum number share this company can have?

Penny stock is coming. EPS at -0.9 lol while now pushing out another 83mil in shares.

This is going to the Moon 🌙 and very Soon! 🚀

Black box warning probably killed it

lost my shirt today with this piece of shit

wow, what a dive

Final count down!

Any news?

Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy - GlobeNewswireReal Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc., to provide multiple health plans with access to an innovative,

will it go up?

Slite brease...finally going UP like a Kite!!!

falling like a little stone down a chasm

The stock appears here at Investing.com gaining .2% at 16.4 usd?

Why so much down again?

Dear bluebird bio, Inc. Stockholder:In January 2021, we announced a transformative milestone for bluebird bio, Inc.—our intent to separate our oncology portfolio and programs from our severe genetic disease portfolio and programs, thereby creating two independent, publicly traded companies. The strategic objectives of the separation are to unlock value, enhance operational performance and strategic flexibility and tailor the capital structures to best serve these distinct businesses.We believe the best way to realize the full potential of this separation is for bluebird bio, Inc. and 2seventy bio, Inc. to operate independently, with distinct management teams and boards of directors dedicated to their unique business strategies. Through this separation, we have the potential to create two focused, durable businesses that are well-positioned with the resources, talent and foundation to be industry leaders in their respective fields.Going forward, bluebird bio, Inc. intends to focus primarily on its programs in severe genetic disease, including betibeglogene autotemcel (beti-cel; formerly LentiGlobin gene therapy for β-thalassemia), LentiGlobin gene therapy for sickle cell disease, and elivaldogene autotemcel (eli-cel; formerly Lenti-D gene therapy for cerebral adrenoleukodystrophy). 2seventy bio, Inc. plans to focus primarily on the discovery and development of novel engineered cell therapies for cancer, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. 2seventy bio, Inc. expects to commercialize idecabtagene vicleucel (ide-cel; being commercialized as Abecma) in the United States and develop bb21217 through its collaboration arrangement with Bristol-Myers Squibb.Upon completion of the separation, 2seventy bio, Inc. will be spun out of bluebird bio, Inc. and established as an independent, publicly traded company. The separation is anticipated to be generally tax-free to bluebird bio, Inc. stockholders. Under the terms of the distribution, each bluebird bio, Inc. stockholder will receive one share of 2seventy bio, Inc. common stock for every three shares of bluebird bio, Inc. common stock held of record on October 19, 2021, the record date for the distribution. You do not need to take any action to receive the common stock of 2seventy bio, Inc. to which you are entitled as a bluebird bio, Inc. stockholder as of the record date.Please read the attached information statement, which is being shared with all bluebird bio, Inc. stockholders as of the record date for the distribution. It describes the separation in detail and contains important information about bluebird bio, Inc. and 2seventy bio, Inc.We thank you for your continued support of bluebird bio, Inc. Sincerely,Daniel S. LynchChairman of the Boardbluebird bio, Inc.